GLP & METABOLIC
AOD-9604
Modified hGH(177-191) fragment. Researched against lipolytic endpoints.
Bundle & save
Free shipment protection · Overnight shipping available · Ships from our Naples, FL facility
Free shipping
on orders over $150
Damage protection
replacement guarantee
Secure checkout
256-bit SSL
Certificate of Analysis
Third-party tested · ISO/IEC 17025 accredited
99%
purity
✓ Passed full QC panel
- Variant
- AOD-9604 · 10 mg
- Lot #
- AML-2026-0508
- Labeled
- 10 mg
- Tested
- 2026-04-15
Full QC panel
- Purity (HPLC)
- 99%
- Net Peptide Content
- Pass
- Identity (HPLC-MS)
- Confirmed
- Heavy Metals (ICP-MS)
- Not detected
- Sterility
- No growth
- Endotoxin (LAL)
- Within limits
Purity, lot and tested date are per-lot; remaining QC rows are representative — exact values on the CoA.
Compound Information
Chemical and structural properties
Chemical identity verified via NIH PubChem · biological targets characterized from the peer-reviewed literature.
Molecular profile
Structure
- CAS Number
- 221231-10-3
- Molecular Formula
- C78H123N23O23S2
- Molecular Weight
- 1815.1 g/mol
- Sequence
- Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe
- Type
- Research peptide
- PubChem
- CID 71300630 ↗
Biological targets
Interactions
- Primary target
- Lipolytic hGH C-terminal domain (β3-adrenergic-linked, proposed)
- Pathway
- Lipolysis / lipogenesis modulation without IGF-1 elevation
- Mechanism
- Modified hGH(176–191) fragment
- Research area
- Lipid metabolism, obesity research
Physical properties
Handling & Storage
- Appearance
- White lyophilized powder
- Solubility
- Soluble in sterile or bacteriostatic water; reconstitute prior to use
- Storage
- 2-8 deg C, protect from light
- Country of origin
- USA
Sources & References
Peer-reviewed research
Indexed in NIH PubMed. Provided for research context; not a claim of clinical outcome.
INTERNATIONAL JOURNAL OF OBESITY AND RELATED METABOLIC DISORDERS : JOURNAL OF THE INTERNATIONAL ASSOCIATION FOR THE STUDY OF OBESITY
Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment
2001 · PMID 11673763
Heffernan MA et al.
View Source ↗RECENT PATENTS ON ENDOCRINE, METABOLIC & IMMUNE DRUG DISCOVERY
Current updates in the medical management of obesity
2012 · PMID 22435392
Khan A et al.
View Source ↗HORMONE RESEARCH
Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone
2000 · PMID 11146367
Ng FM et al.
View Source ↗ENDOCRINOLOGY
The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice
2001 · PMID 11713213
Heffernan M et al.
View Source ↗CURRENT OPINION IN INVESTIGATIONAL DRUGS (LONDON, ENGLAND : 2000)
Obesity drugs in clinical development
2006 · PMID 16625817
Halford JC
View Source ↗
⚠ Important research notice
PRODUCTS ARE INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly prohibited by law. Products should only be handled by licensed, qualified professionals. Products sold are not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food, or cosmetic.
All the research peptides you need, with the peace of mind at your fingertips.
Research updates from Aminologix
Catalog updates, new research compounds, and quality-documentation news. For researchers and labs. No spam, unsubscribe anytime.